References
- Calvaruso G, Vitrano A, Di Maggio R, Lai E, Colletta G, Quota A, Gerardi C, Rigoli LC, Sacco M, Pitrolo L, et al. 2015. Deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial. Am J Hematol. 90(7):634–638.
- Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, et al. 2002. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 118(1):330–336.
- Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. 2003. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 102(5):1583–1587.
- Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F. 2018. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: a randomized controlled trial. Am J Hematol. 93(2):262–268.
- Elalfy MS, Sari TT, Lee CL, Tricta F, El-Beshlawy A. 2010. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 32(8):601–605.
- Maggio A, D’Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, et al. 2002. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 28(2):196–208.
- Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR. 2002. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 100(5):1566–1569.
- Xie Y-Y, Lu Z, Kong X-L, Zhou T, Bansal S, Hider R. 2016. Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones- Attempted optimization of the orally active iron chelator, deferiprone. Eur J Med Chem. 115:132–140.
- Zheng X, Wang X, Ding Z, Li W, Peng Y, Zheng J. 2021. Metabolic activation of deferiprone mediated by CYP2A6. Xenobiotica. 1–33.